Applied Therapeutics, Inc. (APLT)
| Market Cap | 443.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.91M |
| Shares Out | 22.43M |
| EPS (ttm) | -4.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $19.73 |
| Previous Close | $20.22 |
| Change ($) | -0.49 |
| Change (%) | -2.42% |
| Day's Open | 20.04 |
| Day's Range | 19.32 - 20.32 |
| Day's Volume | 147,188 |
| 52-Week Range | 15.44 - 55.47 |
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validat...
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validat...
Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)
Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and imp...
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validat...
Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.
Applied Therapeutics Inc. (NASDAQ: APLT) shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.
Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.
NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against vali...
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against vali...
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against vali...
LOS ANGELES--(BUSINESS WIRE)---- $APLT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Inves...
LOS ANGELES--(BUSINESS WIRE)---- $APLT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Applied Therapeutics, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Applied Therapeutics, Inc.
BENSALEM, Pa.--(BUSINESS WIRE)---- $APLT #fraud--INVESTOR ALERT: Law Offices of Howard G.
LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. ...
NEW YORK, Aug. 18, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc.
NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valid...
In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $25.93, marking a +0.5% move from the previous day.
Applied Therapeutics Inc. (APLT) closed the most recent trading day at $25.74, moving +1.74% from the previous trading session.
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
NEW YORK, July 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valid...
Is (APLT) Outperforming Other Medical Stocks This Year?
On July 1, 2020, a fraudulent “short report” was posted.
Applied Therapeutics (APLT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
AT-007 pediatric Galactosemia study (ACTION-Galactosemia Kids) initiated
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valid...
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valida...
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valida...
New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients
NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unm...
Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
These three clinical-stage biotechs could all double in value before year's end.
While the record rally in Tesla stock has garnered all the attention over the past six months, these growth stocks have been just as hot.
NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidat...
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidat...
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidat...
As of late, it has definitely been a great time to be an investor Applied Therapeutics.
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Applied Therapeutics (APLT) news for Wednesday concerning positive results from a clinical trial have APLT stock rocketing higher. The post Applied Therapeutics News: APLT Stock Shoots 32% Hig...
Stellar results from a phase 2 study have investors excited about the biotech's prospects.
Shares of Applied Therapeutics Inc. APLT, -2.06% jumped 27% in premarket trading on Wednesday after the company said it had positive results from a Phase-2 clinical trial testing AT-007 as a t...
AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board,...
About APLT
Applied Therapeutics, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 f... [Read more...]
| Industry Biotechnology | IPO Date May 14, 2019 |
| CEO Dr. Shoshana Shendelman Ph.D. | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol APLT |
Analyst Forecasts
According to 7 analysts, the average rating for APLT stock is "Strong Buy." The 12-month stock price forecast is 53.00, which is an increase of 168.63% from the latest price.